XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.1
License Agreements - Novartis (Details) - Novartis - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 161 Months Ended
Nov. 30, 2009
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Dec. 31, 2022
License Agreements          
Royalties payable   $ 276.9   $ 276.9 $ 253.5
JAKAFI | UNITED STATES          
License Agreements          
Royalties payable on net sales   23.4 $ 21.7    
JAKAFI | Non-US          
License Agreements          
Royalties payable on net sales   76.7 70.9    
TABRECTA PROD SERV | Non-US          
License Agreements          
Royalties payable on net sales   $ 4.2 $ 3.5    
Minimum | JAKAVI          
License Agreements          
Royalty payments on future global net sales (as a percent)   12.00%      
Maximum | JAKAVI          
License Agreements          
Royalty payments on future global net sales (as a percent)   14.00%      
Development Milestones          
License Agreements          
Amount recognized and received for the achievement of a predefined milestone       157.0  
Development Milestones | Maximum          
License Agreements          
Upfront and immediate milestone payment to be received under license agreement $ 174.0        
Regulatory Milestones          
License Agreements          
Amount recognized and received for the achievement of a predefined milestone       340.0  
Regulatory Milestones | Maximum          
License Agreements          
Upfront and immediate milestone payment to be received under license agreement 495.0        
Commercialization Milestones          
License Agreements          
Amount recognized and received for the achievement of a predefined milestone       $ 200.0  
Commercialization Milestones | Maximum          
License Agreements          
Upfront and immediate milestone payment to be received under license agreement 500.0        
Development and Regulatory Milestones | Maximum          
License Agreements          
Upfront and immediate milestone payment to be received under license agreement $ 75.0